From blur to breaktHrough
We read the immune system in high definition, to help predict what it's going to do next.
Highlights
Our science
From a blood sample, we resolve up to 2,500 immune cell subsets and measure more than 100 million data points. Our aim is to read each patient's immune system in enough detail to predict how it will respond.
For decades, the immune system has been mapped with tools too blunt to capture its complexity. Most look at a handful of markers. We look at the whole system.
Our Programmes
We're starting where knowing the immune system's next move matters most: transplantation and immuno-oncology. Three programmes put HD Immunology™ to work.
HSCT
Developing a predictive screening tool for relapse and graft-versus-host disease after Hematopoietic Stem Cell Transplantation
SOT
Creating the tools to spot the signatures of early graft rejection in Solid Organ Transplantation
I-O
Identifying immune signatures that may predict who responds to checkpoint inhibitors, and who has severe adverse events
PARTNERING WITH IMU
We are working with partners across the spectrum of immune health and disease.
IMU Biosciences works with clinical research groups, pharma, biotech and diagnostics companies. We're one of the partners in MANIFEST, the UK consortium led by the Francis Crick Institute and the Royal Marsden NHS Foundation Trust, studying why patients respond to, or have side effects from, cancer immunotherapy.
Together, we will uncover disease mechanisms, improve drug discovery and development and deliver immune-driven precision medicine.
About Us
Our work builds on more than a decade of immune profiling research dedicated to understanding the complexity of the human immune system
We're immunologists, computational biologists, data scientists and engineers. Our mission is to read the immune system in enough detail to say what happens next, for research, a transplant, a therapy or a diagnosis that's still a biopsy away.
OUr INVESTORS
